Multivalent Antibody Constructs for Broad Influenza Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for addressing influenza infections, including vaccines and antiviral drugs, face challenges such as predicting viral strains, delayed vaccine availability, poor immunogenicity in certain groups, limited production capacity, and the emergence of resistant strains, while monoclonal antibodies have limitations like high cost, incomplete coverage, and risk of resistance.
Innovation Solution
Development of novel single domain antibodies (sdAbs) and multi-domain antibodies capable of binding to and neutralizing multiple influenza A and B virus strains across different phylogenetic groups, including H1, H3, H5, H7, and B/Yamagata/Victoria lineages, offering broad cross-neutralization and stability for use as diagnostic, prophylactic, and treatment agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used for influenza treatment, then neutralization of viral strains is achieved, but production cost increases and coverage is incomplete
Solution Approach 1:
The patent applies universality by designing binding molecules that can recognize and bind to multiple different influenza virus subtypes (H1, H3, H5, H7 from phylogenetic group 1 and H3, H7 from phylogenetic group 2) through a single molecular structure. The binding molecules target conserved epitopes in the hemagglutinin protein that are common across different viral strains, enabling one molecule to perform multiple neutralization functions against diverse influenza variants.
Solution Approach 2:
The patent employs parameter changes by modifying the structural parameters of antibody fragments to create binding molecules with altered binding characteristics. Specifically, the invention uses single domain antibodies (sdAbs) and multi-domain antibody constructs that differ from conventional monoclonal antibodies in their domain architecture, allowing them to access conserved epitopes in the hemagglutinin stem region that are less variable across subtypes, thereby achieving broader coverage.
2Reliability
If vaccines are implemented for influenza prevention, then immune protection is provided, but production capacity is limited and availability is delayed
Solution Approach 1:
The patent applies copying by creating recombinant binding molecules that can be produced through genetic engineering in cell culture systems. Instead of relying on traditional vaccine production methods that require growing large quantities of virus, the invention copies the protective function of natural antibodies by synthesizing identical or similar binding molecules recombinantly, enabling scalable production without the limitations of viral culture capacity.
Solution Approach 2:
The patent substitutes the mechanical/biological system of traditional vaccine production (which requires virus cultivation, purification, and quality control of live or inactivated virus) with a biochemical production system using recombinant DNA technology. The binding molecules are produced by transfecting host cells with expression vectors, allowing controlled, scalable production that is not constrained by viral growth requirements.
3Reliability
If antiviral drugs are used for influenza treatment, then viral replication is inhibited, but resistant strains emerge and adverse effects occur
Solution Approach 1:
The patent uses binding molecules as intermediaries that physically block the interaction between influenza virus hemagglutinin and host cell receptors. These molecules act as mediators that prevent viral attachment and entry into cells without requiring intracellular viral replication inhibition, thereby avoiding the selection pressure that leads to resistance development against antiviral drugs that target viral enzymes.
4Ease of manufacture
If single domain antibodies are developed for influenza binding, then production cost decreases and coverage broadens, but neutralization potency must be maintained
Solution Approach 1:
The patent applies merging by combining multiple single domain antibodies into multi-domain antibody constructs. This merging of multiple binding units allows the molecule to achieve higher avidity and potency through cooperative binding to multiple epitopes on the viral hemagglutinin, compensating for the potentially lower affinity of individual sdAbs while maintaining the cost advantages of sdAb production.
Data Source
AI summary
Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.